CareSens Air 3
i-SENS
What it is
An investigational i-SENS CGM identified in an adult T1D accuracy study. The registry still says recruiting despite an elapsed estimated completion date; no results or market authorization are established.
Editorial review: . What was checked and what remains uncertain.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Accuracy: Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the record-specific review limits for gaps in evidence, source access or availability checks.
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 35 × 20 + 35 × 15 + 35 × 15 + 35 × 10 + 35 × 10 + 35 × 10 + 35 × 10 + 0 × 5 + 0 × 5 = 3150; divide by total weight 100. Unrounded weighted result: 31.5.
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Provisional editorial assessment: the accuracy-study record does not establish a final product specification or clinical benefit for this criterion.[1]
Editor’s take
A named clinical development program merits tracking. Its specifications and relationship to Air2 remain unconfirmed; provisional scores must not be read as measured performance.
The full picture
CareSens Air 3 is named in i-SENS study NCT07296276, an adult T1D accuracy and precision study with estimated enrollment of 32. The record last updated 9 April 2026 still lists recruiting and an estimated completion of 30 April 2026. An elapsed forecast is not confirmation that recruitment or the study has finished; no results are posted.1
This record establishes the investigational device name, not an approved age indication, successful accuracy outcome or launch date. The available study record does not establish whether Air 3 is a renamed Air 2, a different platform or a regional variant, so these records remain separate.
References
-
ClinicalTrials.gov NCT07296276, checked 16 September 2026. https://clinicaltrials.gov/study/NCT07296276 ↩
Coming soon
ETA · No commercial launch date verified
Sources
- [1]NCT07296276 CareSens Air3 accuracy and precision study · registry